Unpacking the Latest Options Trading Trends in Viking Therapeutics
Financial giants have made a conspicuous bearish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 34 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $146,300, and 29 were calls, valued at $2,404,204.
What’s The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $105.0 for Viking Therapeutics over the last 3 months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics’s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics’s whale trades within a strike price range from $15.0 to $105.0 in the last 30 days.
Viking Therapeutics 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 12/20/24 | $9.0 | $8.6 | $8.9 | $75.00 | $213.6K | 745 | 252 |
| VKTX | CALL | SWEEP | BULLISH | 01/16/26 | $62.9 | $59.0 | $61.34 | $15.00 | $191.7K | 154 | 31 |
| VKTX | CALL | TRADE | NEUTRAL | 12/20/24 | $8.1 | $7.5 | $7.8 | $77.50 | $187.2K | 14 | 493 |
| VKTX | CALL | SWEEP | BULLISH | 01/17/25 | $25.5 | $25.3 | $25.5 | $50.00 | $127.5K | 863 | 360 |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $25.5 | $25.4 | $25.4 | $50.00 | $127.0K | 863 | 310 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company’s clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics, we pivot to a closer look at the company’s own performance.
Present Market Standing of Viking Therapeutics
- Currently trading with a volume of 2,977,355, the VKTX’s price is down by -1.41%, now at $73.47.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 99 days.
Professional Analyst Ratings for Viking Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $90.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $90.
* Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with Benzinga Pro for real-time alerts.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leave a Reply